These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16925505)

  • 41. Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report.
    Amer-Salas N; González-Morcillo G; Rodríguez-Camacho JM; Cladera-Serra A
    J Oncol Pharm Pract; 2021 Jan; 27(1):244-249. PubMed ID: 32517638
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL.
    Horibe K; Takimoto T; Yokozawa T; Makimoto A; Kobayashi Y; Ogawa C; Ohno R; Koh N; Katsura K; Tobinai K
    Rinsho Ketsueki; 2011 Jun; 52(6):406-15. PubMed ID: 21737993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
    Lech-Maranda E; Korycka A; Robak T
    Mini Rev Med Chem; 2009 Jun; 9(7):805-12. PubMed ID: 19519505
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
    Candoni A; Lazzarotto D; Petruzzellis G
    Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
    Kumamoto T; Goto H; Ogawa C; Hori T; Deguchi T; Araki T; Saito AM; Manabe A; Horibe K; Toyoda H
    Int J Hematol; 2020 Nov; 112(5):720-724. PubMed ID: 32761462
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
    Larson RA
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S13-20. PubMed ID: 18086342
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clofarabine.
    Drugs R D; 2004; 5(4):213-7. PubMed ID: 15230627
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nelarabine use in leukemias.
    Kisor DF
    Drugs Today (Barc); 2006 Jul; 42(7):455-65. PubMed ID: 16894400
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
    Karthik U; Motwani J
    J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature.
    Aguayo A; Cortes JE; Kantarjian HM; Beran M; Gandhi V; Plunkett W; Kurtzberg J; Keating MJ
    Cancer; 1999 Jan; 85(1):58-64. PubMed ID: 9921974
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.
    Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
    BMC Cancer; 2014 Jul; 14():547. PubMed ID: 25070259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells.
    Rodriguez CO; Legha JK; Estey E; Keating MJ; Gandhi V
    Clin Cancer Res; 1997 Nov; 3(11):2107-13. PubMed ID: 9815603
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
    Shimony S; DeAngelo DJ; Luskin MR
    Blood Adv; 2024 Jan; 8(1):23-36. PubMed ID: 37389830
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Central nervous system neurotoxicity associated with nelarabine in T-cell acute lymphoblastic leukemia.
    Pehlivan UA; Gürkan E; Açar İH; Bıçakcı YK
    J Oncol Pharm Pract; 2023 Jan; 29(1):246-251. PubMed ID: 35593112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The long and winding road of the clinical development of Nelarabine.
    Kurtzberg J
    Leuk Lymphoma; 2007 Jan; 48(1):1-2. PubMed ID: 17325839
    [No Abstract]   [Full Text] [Related]  

  • 56. Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater?
    Malone A; Smith OP
    Br J Haematol; 2017 Oct; 179(2):179-181. PubMed ID: 28891074
    [No Abstract]   [Full Text] [Related]  

  • 57. Nelarabine (Arranon) for T-cell acute lymphoblastic leukemia.
    Med Lett Drugs Ther; 2006 Feb; 48(1228):14-5. PubMed ID: 16467734
    [No Abstract]   [Full Text] [Related]  

  • 58. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine.
    Rodriguez CO; Stellrecht CM; Gandhi V
    Blood; 2003 Sep; 102(5):1842-8. PubMed ID: 12750168
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival.
    Forcade E; Leguay T; Vey N; Baruchel A; Delaunay J; Robin M; Socié G; Dombret H; Peffault de Latour R; Raffoux E
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1124-6. PubMed ID: 23648236
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Older and new purine nucleoside analogs for patients with acute leukemias.
    Robak P; Robak T
    Cancer Treat Rev; 2013 Dec; 39(8):851-61. PubMed ID: 23566572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.